Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. (Q53149368)

From Wikidata

Jump to navigation Jump to search

scientific article published on 26 July 2011

Language	Label	Description	Also known as
English	Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.	scientific article published on 26 July 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21788967%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21788967%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21788967%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

S H Lee

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21788967%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

S J Kim

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21788967%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

J H Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21788967%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

J C Kim

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21788967%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

J Y Lee

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21788967%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

26 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21788967%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Prostate Cancer and Prostatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21788967%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21788967%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21788967%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

320-325

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21788967%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

https://scigraph.springernature.com/pub.10.1038/pcan.2011.22

0 references

Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

21 January 2018

Natural history of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

21 January 2018

Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

21 January 2018

A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

21 January 2018

Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

21 January 2018

Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

21 January 2018

Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

21 January 2018

Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

21 January 2018

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

21 January 2018

The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

21 January 2018

Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

21 January 2018

Place of overactive bladder in male lower urinary tract symptoms

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

21 January 2018

The urologist's view of male overactive bladder: discrepancy between reality and belief in practical setting.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

21 January 2018

Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

21 January 2018

Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

21 January 2018

Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

21 January 2018

Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicen

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

21 January 2018

Measurement characteristics of a voiding diary for use by men and women with overactive bladder

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

21 January 2018

Behavioral vs Drug Treatment for Urge Urinary Incontinence in Older Women

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

21 January 2018

The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

31 March 2020

Differential diagnosis of overactive bladder in men

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

31 March 2020

Urodynamic characterization of nonobstructive voiding dysfunction in symptomatic elderly men

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

31 March 2020

Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

31 March 2020

Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

31 March 2020

Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

31 March 2020

Prevalence and burden of overactive bladder in the United States

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.22

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53149368&oldid=1460148681"